within Pharmacolibrary.Drugs.ATC.N;

model N05CM05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0205,
    adminDuration  = 600,
    adminMass      = 0.0004,
    adminCount     = 1,
    Vd             = 0.0087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Scopolamine is an anticholinergic agent used to prevent nausea and vomiting caused by motion sickness or anesthesia and surgery. It acts as a competitive antagonist of muscarinic acetylcholine receptors. Scopolamine is approved and used today, commonly administered via transdermal patches or other parenteral routes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li>Ulf D Renner, Reinhard Oertel, Wilhelm Kirch,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.,Therapeutic drug monitoring,2005<a href='https://pubmed.ncbi.nlm.nih.gov/16175141/'>https://pubmed.ncbi.nlm.nih.gov/16175141/</a></li><li>Andrea Pensado, Laura Hattam, K A Jane White, Anita McGrogan, Annette L Bunge, Richard H Guy, M Bego√±a Delgado-Charro,Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling.,Molecular pharmaceutics,2021<a href='https://pubmed.ncbi.nlm.nih.gov/34124907/'>https://pubmed.ncbi.nlm.nih.gov/34124907/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05CM05;
